Back to mobile site

More on BBIO

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+35.8% Growth)
- Ratings (8.9 Score)
- Holders

Upcoming Events

- Earnings (10/29/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

BridgeBio Pharma (NQ:BBIO)
Delayed: 72.44 --0 (-0%)
Prev. Close $72.44  
Open$72.44 
52 Wk High$ 
52 Wk Low$ 
Day High$72.44 
Day Low$72.44 
P/E N/A  
EPS$ 
Volume110,600 

Friends, Peers and Foes (?): PFE, ARGX, CNTA, IONS, BIIB (more...)

Sep 11, 2026 08:43 AM BridgeBio Pharma (BBIO) PT Lowered to $23 at JPMorgan
Sep 10, 2026 06:49 AM H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
Sep 9, 2026 04:00 AM BridgeBio reports infigratinib trial data on sleep apnea, ear infections
Sep 9, 2026 04:00 AM Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
Sep 2, 2026 07:30 AM BridgeBio to present infigratinib data at ESPE meeting in September
Sep 2, 2026 07:30 AM BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
Sep 2, 2026 06:55 AM H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
Sep 1, 2026 07:30 AM BridgeBio to Participate in September Investor Conferences
Aug 31, 2026 03:08 PM Trump announces nine more pharma firms in drug pricing deals
Aug 31, 2026 01:59 PM BridgeBio Pharma (BBIO) PT Raised to $110 at Mizuho
View All Articles

Entities mentioned with BBIO

View All Entities